News | October 25, 2024
Jagsonpal Pharmaceuticals Q2 FY25 net profit up at Rs. 11.45 Cr
Jagsonpal Pharmaceuticals has reported total income of Rs. 76.34 crores during the period ended September 30, 2024
Jagsonpal Pharmaceuticals has reported total income of Rs. 76.34 crores during the period ended September 30, 2024
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%
Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
SIBUR is developing a special grade of polycarbonate compatible with radiation sterilization
The company can now expand its business horizon into the area of pharmaceutical applications in the USA
Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic
Lamotrigine extended-release tablets are indicated for adjunctive therapy for primary generalized tonic-clonic seizures and partial-onset seizures
Lupin's Pithampur Unit-1 gets Form 483 from USFDA with 3 observations
The sample seized by CDSCO is not manufactured by Torrent and is in fact non-genuine and spurious
Subscribe To Our Newsletter & Stay Updated
